Dyne Therapeutics, Inc. $DYN Shares Purchased by Armistice Capital LLC

Armistice Capital LLC increased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 6.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,249,708 shares of the company’s stock after purchasing an additional 185,708 shares during the period. Dyne Therapeutics makes up approximately 0.8% of Armistice Capital LLC’s holdings, making the stock its 18th biggest holding. Armistice Capital LLC’s holdings in Dyne Therapeutics were worth $63,564,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strs Ohio acquired a new position in Dyne Therapeutics during the 4th quarter worth approximately $51,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics during the 4th quarter worth approximately $84,000. Steward Partners Investment Advisory LLC lifted its position in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $111,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $19.20 on Thursday. The business’s 50 day moving average is $18.27 and its two-hundred day moving average is $18.10. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -5.96 and a beta of 1.09. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) EPS. Analysts forecast that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on DYN shares. Morgan Stanley cut their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.85.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 83,219 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the sale, the director directly owned 7,962 shares of the company’s stock, valued at approximately $144,749.16. This represents a 91.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas Kerr sold 1,564 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $28,715.04. Following the sale, the insider directly owned 170,042 shares in the company, valued at approximately $3,121,971.12. This represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders acquired 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is currently owned by insiders.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.